Shuttle Pharmaceuticals Holdings, Inc. · NASDAQ:SHPH

Shuttle Pharmaceuticals — Investor Presentation (May 2024)

14 slides from Shuttle Pharmaceuticals's investor presentation, May 23, 2024

1. Slide 1: Shuttle Pharmaceuticals Holdings, Inc. Investor Presentation

   Shuttle Pharmaceuticals Holdings, Inc. Nasdaq: SHPH Investor Presentation May 2024

2. Slide 2: Forward Looking Statements

   Forward Looking Statements All of the information contained within this business presentation (the “Presentation”) has been obtained from sources generally believed to be reliable by Shuttle Pharmaceuticals Holdings, Inc. (referred to herein as “Shuttle Pharmaceuticals,” “Shuttle Pharma” or the “Com

3. Slide 3: The Fundamental Problem of Radiation Therapy

   The Fundamental Problem of Radiation Therapy: Cancers are surrounded by radiation sensitive, dose-limiting normal tissues Sensitization of cancer cells to radiation therapy  The radiation dose determines cancer curability  Adjacent normal tissues are dose-limiting Sensitizer  Radiation sensitizer

4. Slide 4: Company Overview

   Company Overview Shuttle Pharma (Nasdaq: SHPH) is a clinical-stage pharmaceutical company, developing next generation drugs and diagnostics to improve outcomes for cancer patients treated with radiation therapy (RT). Therapeutics  Ropidoxuridine is a clinical stage, orally-administered cancer radia

5. Slide 5: Radiation Sensitization, Immune Modulation, Diagnostics and Theranostics

   Radiation Sensitization Cancers resistant to cure by radiation therapy alone due to adjacent radiation sensitive normal tissues can be more effectively treated by Ropidoxuridine + RT Radiation sensitization and immune modulation Selective HDAC6 inhibitors stimulate to immune system against radiation

6. Slide 6: Ropidoxuridine (IPdR) – How does it work?

   Ropidoxuridine (IPdR) – How does it work? Ropidoxuridine (IPdR) is the prodrug of IUdR Ropidoxuridine (IPdR) is metabolized to  IUdR is a powerful radiation sensitizer showing Phase II efficacy in NIH sponsored clinical IUdR, incorporates into DNA, and trials in glioblastoma, anaplastic astrocytoma

7. Slide 7: Ropidoxuridine (IPdR) – Clinical Development

   Ropidoxuridine (IPdR) – Clinical Development  Phase I and pharmacology study of Ropidoxuridine (IPdR) and RT (Clin Cancer Res, 2019).  18 patients reached an MTD of Ropidoxuridine with RT of 1200 mg daily for 28 days  14 patients were assessed for tumor responses: 4 partial responses, 9 stable di

8. Slide 8: SP-2-225: Selective HDAC6 Inhibitor – How does it work?

   SP-2-225: Selective HDAC6 Inhibitor – How does it work? SP-2-225 inhibits HDAC6, prolongs macrophage polarization in M-1 state, resulting in an enhanced inflammatory Acetylated histones Active transcription response to immunogenic cancers and Irradiated tumors. De-acetylated histones Inactive transc

9. Slide 9: Intellectual Property

   Intellectual Property Ropidoxuridine (radiation sensitizers)  Orphan disease designation, next generation IPdR/TPI formulation Selective HDAC inhibitors (radiation sensitizers/immune modulators)  HDAC6 selective SP-2-225, Class I HDAC inhibitor SP-1-303 PC-RAD Test (predictive biomarker)  Metabol

10. Slide 10: Clinical Development Strategy - Priorities

    Clinical Development Strategy - Priorities  Therapy Priority #1: Clinical development of Ropidoxuridine & RT  Perform the Phase II clinical trial of Ropidoxuridine & RT in brain tumors  Seek FDA “breakthrough” designation and early marketing approval on glioblastoma  Prepare Ropidoxuridine & RT

11. Slide 11: Financial Overview

    Financial Overview Shuttle Pharmaceuticals Capital Market Profile Cap Table as of March 31, 2024 Common Stock 16,819,893 Exchange/Ticker NASDAQ: SHPH Fully Vested Restricted Stock Units (RSUs) 125,000 Closing Stock Price* $0.42 RSUs Outstanding 272,855 52 Wk High/Low* $0.35 - $2.75 Warrants Outstand

12. Slide 12: Shuttle’s Experienced Leadership Team

    Shuttle’s Experienced Leadership Team  Founder & CEO of Shuttle  Served as President  Served as CFO of Pharma since 2012; Chairman, & COO of Shuttle Shuttle Pharma since Board of Directors 2017 Pharma since 2012 2019  Member, Board of Directors,  MBA George  MHSA George Neopharm Inc. 1990 Wash

13. Slide 13: Board of Directors

    Board of Directors Steve Richards, MBA, CPA Milton Brown, MD, PhD Bette Jacobs, PhD Chris Senanayake, PhD Joshua Schafer, MBA Businessman Vice Dean for Research Professor/Distinguished Scholar Chief Commercial Officer CEO, TCG GreenChem CEO, Endurance Media East Virginia Medical School Georgetown Un

14. Slide 14: THANK YOU

    THANK YOU Shuttle Pharmaceuticals Holdings, Inc. Anatoly Dritschilo, MD, CEO Tel: (240) 403-1212 Email: anatoly.dritschilo@ShuttlePharma.org Investor Relations Lytham Partners Robert Blum Tel: (602) 889-9700 Email: SHPH@LythamPartners.com

Shuttle Pharmaceuticals Holdings — Investor Presentation (May 2024) on 6ix